Biotech Company Takes on Convertible Debt While Building Crypto Treasury

Enlivex Therapeutics, a Nasdaq-listed company that started out focused on clinical-stage immunotherapy, has closed a $21 million convertible debt deal as it expands its exposure to decentralized prediction markets through RAIN token holdings. The financing, announced March 23, 2026, comes four months after a large private placement that positioned the firm as an unusual bridge between biotech and Web3. A single institutional investor provided the full amount, which tells you something about Enlivex's strategy: grow the crypto treasury while still advancing its core osteoarthritis treatment.

The debt comes structured as a senior secured convertible note maturing in March 2027. The conversion price sits at $2.69175 per share—a 264% premium over where the stock closed on March 20, 2026. After fees, Enlivex nets about $18.7 million, with repayment spread across nine monthly installments. The note is secured by Enlivex's digital asset accounts, specifically its RAIN tokens. RAIN runs on Arbitrum as part of a permissionless predictions and options protocol.

Alongside the financing, Enlivex exercised part of an existing option to buy roughly 3.03 billion RAIN tokens for $10 million at $0.0033 per token—62% below where RAIN closed on March 22, 2026. The company also pushed out its option to purchase up to 272.12 billion more RAIN tokens through December 31, 2027, at the same price. This expands a treasury that Enlivex preliminarily values at around $607 million in RAIN holdings as of December 31, 2025, though that number is subject to audit.

The board also approved a $20 million share repurchase program with no set expiration. The buyback is meant to support shareholder value during these treasury moves, though it remains subject to regulatory requirements and market conditions.

| Detail | Information | |-------------------------|-----------------------------------------------------------------------------| | Project | Enlivex Therapeutics Ltd. (Nasdaq: ENLV) | | Sector / Category | Biotech (immunotherapy) with Web3 treasury (prediction markets via RAIN) | | Funding Round | Debt Financing (senior secured convertible note) | | Amount Raised | $21 million (gross); net proceeds ~$18.7 million | | Valuation | Undisclosed; conversion price $2.69175 per share (264% premium) | | Lead Investor | Lind Global Asset Management XIV, LLC | | Notable Participants | Single-investor deal; no additional participants disclosed | | Disclosure Gaps | Use of funds not explicitly specified beyond treasury and repurchase support |

Treasury Moves Point to Wider Sector Shifts

This financing follows Enlivex's pivot that started in November 2025 with a $212 million private placement. That deal funded the initial RAIN token accumulation and made the company the first U.S.-traded public entity to build a treasury around prediction market tokens. RAIN operates as a decentralized protocol—think Uniswap but for prediction markets—with AI-resolved outcomes and a deflationary buyback mechanism tied to its governance token.

Enlivex hasn't abandoned its drug development work. Allocetra, its Phase 2b-ready therapy for knee osteoarthritis (a condition affecting over 300 million people worldwide), remains in the pipeline. But the treasury strategy gives the company indirect exposure to prediction markets, a space that's been drawing serious institutional money. NYSE's parent company put $2 billion into Polymarket. Kalshi raised $300 million from Andreessen Horowitz and Sequoia. Enlivex is playing in the same arena via RAIN on Arbitrum.

Here's what matters about this deal:

• Lind Global provided the entire $21 million, taking Enlivex's crypto assets as security to reduce their risk.
• The partial RAIN option exercise added 3.03 billion tokens to holdings. Extended purchase rights mean the treasury could grow substantially if RAIN performs well.
• The $20 million buyback authorization could offset dilution from note conversions while also signaling management believes in the underlying assets.
• Enlivex is framing this as part of a "Quality Longevity" focus—biotech development (Allocetra showed 72% pain reduction in trials) combined with crypto treasury for diversified reserves.

The company has hit some recent milestones: FDA IND clearance for Allocetra's Phase 2b trial in knee osteoarthritis, plus RAIN listings on Kraken and KuCoin. The stock gained 8.82% on March 23, 2026, while biotech peers showed mixed performance—suggesting investors responded to both the clinical and crypto news.

Enlivex shares closed at $1.11 with volume running 28% above the 20-day average and holding above the 200-day moving average. The board, which added former Italian Prime Minister Matteo Renzi in late 2025, now oversees this hybrid model that combines macrophage reprogramming immunotherapy with blockchain-based treasury management.

Bottom line: Investors continue to show interest in biotech companies adding Web3 treasury strategies, and deals like this suggest the lines between sectors are blurring faster than many expected.